Clinical trials investigating systemic therapies for uHCC have traditionally excluded patients with CP B cirrhosis, reflecting concerns regarding safety and diminished liver reserve. This study addresses this crucial gap by performing a single-center, retrospective analysis of 94 uHCC patients treated with ICIs plus AAs between 2020 and 2024. Among them, 63 had Child-Pugh A (CP A) cirrhosis, while 31 presented with CP B cirrhosis, allowing for a comparative evaluation of treatment outcomes and tolerability.

The study’s findings reveal an encouraging overall objective response rate (ORR) of 44.7% across the whole cohort, with a disease control rate (DCR) of 72.3%. These clinical endpoints offer a promising perspective on the tumor response to combination therapy in a population with traditionally poor prognoses. Median progression-free survival (mPFS) was reported at 6.3 months, and notably, the median overall survival (mOS) reached 28.3 months, underscoring sustained benefits in systemic therapy for uHCC patients.

When stratified by liver function status, patients with CP A cirrhosis exhibited higher ORR (50.8%) compared to those with CP B cirrhosis (32.3%), though this difference approached but did not reach statistical significance (P = 0.089). Similarly, DCR and mPFS were numerically superior in the CP A group but lacked statistical significance. Intriguingly, mOS demonstrated a marked and statistically significant disparity, favoring the CP A group (39.2 months) over CP B patients (15.9 months, P = 0.035). This dichotomy highlights the profound impact of hepatic functional reserve on long-term survival despite comparable response rates to therapy.

Several prognostic factors independent of cirrhosis status emerged from the analysis. Poor performance status, denoted by an Eastern Cooperative Oncology Group (ECOG) score of 2, prior treatments, and absence of concurrent locoregional therapies were associated with diminished objective responses. Additionally, CP B cirrhosis and advanced Barcelona Clinic Liver Cancer (BCLC) stages C or D independently predicted worse overall survival, underscoring the nuanced interactions between tumor burden, liver function, and systemic therapy efficacy.

The safety profile of ICIs combined with AAs was carefully assessed, revealing that an overwhelming majority (93.6%) of patients experienced at least one treatment-related adverse event (TRAE), with 27.7% encountering grade 3 or higher toxicities. Crucially, the incidence and severity of TRAEs did not differ significantly between CP A and CP B subgroups, suggesting that the addition of ICIs and AAs does not disproportionately increase treatment-related risks even in patients with moderately impaired liver function.

Remarkably, 32.3% of patients with CP B cirrhosis demonstrated improvement in their Child-Pugh score following systemic therapy, indicating a potential for therapeutic intervention to not only control tumor progression but also enhance hepatic functional reserve. This finding challenges conventional therapeutic nihilism associated with CP B patients and advocates for a more inclusive approach in clinical practice.

Understanding the mechanistic underpinnings of ICIs combined with AAs in uHCC is essential. Immune checkpoint inhibitors function by unleashing the immune system’s cytotoxic T cells against tumor cells, a mechanism often suppressed in the tumor microenvironment. Antiangiogenic agents complement this by inhibiting vascular endothelial growth factor (VEGF) pathways, effectively starving the tumor of its blood supply and promoting an immunologically active milieu. Their synergy is thought to enhance antitumor immunity and counteract resistance pathways frequently encountered in hepatocellular carcinoma.

The study’s retrospective design, although inherently limited by potential selection biases and confounding variables, offers valuable real-world insights. Incorporating patients with CP B cirrhosis, typically excluded from randomized trials, enhances the generalizability of findings and contributes toward personalized treatment paradigms. However, larger, prospective studies are essential to validate these observations and elucidate optimal treatment sequencing and combination strategies.

Previous research on systemic therapies in uHCC mainly focused on patients with preserved liver function, limiting evidence for CP B populations. This study significantly advances the field by demonstrating that systemic immunotherapy combined with antiangiogenic treatment can be both efficacious and tolerable in these patients, opening new therapeutic avenues. The observed survival benefit and Child-Pugh score improvements further emphasize the need to reconsider exclusion criteria in future clinical trials.

Translating these findings into clinical practice necessitates careful patient selection and monitoring. While ICIs plus AAs show robust efficacy, attention to adverse events remains paramount, particularly in patients with compromised liver function. The comparable safety profiles between Child-Pugh groups provide reassurance but warrant vigilant management to optimize outcomes.

The integration of locoregional therapies alongside systemic treatments appeared to improve objective response rates, underscoring the potential benefit of multimodal approaches in managing uHCC. Combining transarterial chemoembolization, radiofrequency ablation, or other localized interventions with ICIs and AAs may potentiate antitumor effects and prolong survival, as suggested by the independent predictive value of simultaneous locoregional therapy.

Moreover, patient performance status remained a critical determinant of treatment success, emphasizing the importance of pre-treatment evaluation and supportive care to maintain functional capacity. Incorporating comprehensive assessments and potential interventions to improve performance status might broaden eligibility and enhance clinical benefit.

This study’s implications extend beyond clinical outcomes, prompting a paradigm shift in conceptualizing systemic therapy candidacy for uHCC patients with advanced liver disease. By demonstrating safety and efficacy in CP B patients, it challenges existing treatment algorithms and supports a more nuanced, inclusive therapeutic approach balancing risk and benefit.

In conclusion, the retrospective analysis conducted at Beijing You’an Hospital highlights the promise of combining immune checkpoint inhibitors with antiangiogenic agents in the management of unresectable hepatocellular carcinoma among patients with varied liver function statuses. While significant survival differences remain linked to hepatic reserve, the overall favorable safety profile and some improvements in liver function underscore the potential to expand treatment access and improve outcomes for historically underserved patient groups in oncology.

Further well-structured prospective trials with larger cohorts and longer follow-up are imperative to refine patient stratification, optimize dosing regimens, and elucidate combinatory strategies involving ICIs, AAs, and locoregional therapies. Such investigations will be foundational to establishing new standards of care in hepatocellular carcinoma treatment, ultimately aiming to enhance survival and quality of life for patients within this challenging clinical context.

Subject of Research: Evaluation of the efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in unresectable hepatocellular carcinoma patients with Child-Pugh A versus B cirrhosis.

Article Title: Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study.

Article References:
Liu, D., Yang, Z., Wang, L. et al. Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study. BMC Cancer 25, 1651 (2025). https://doi.org/10.1186/s12885-025-15126-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15126-4

This ground-breaking research centers on the metabolic enzyme ATP citrate lyase (ACLY), a key catalyst in the biochemical conversion of glucose to lipid molecules within liver cells. Tumor cells notoriously hijack this metabolic pathway, exploiting fat synthesis to fuel their unchecked growth and survival. The team at McMaster engineered a pharmacological agent — EVT0185 — designed to selectively inhibit ACLY activity within hepatic tissues. This targeted approach interrupts the tumor’s metabolic lifeline, substantially stunting its progression while sparing other organs from systemic side effects.

Strikingly, the treatment did more than halt tumor growth; it revitalized the immune environment within the liver. Conventional cancer immunotherapy paradigms emphasize the pivotal role of cytotoxic T lymphocytes (CTLs) in recognizing and eradicating cancer cells. However, the McMaster study revealed a surprising actor in the anti-tumoral immune orchestra: B cells. These antibody-producing lymphocytes, long overshadowed by T cells in cancer research, emerged as critical mediators of tumor clearance following ACLY inhibition.

The enhanced immunogenicity of liver tumors post-treatment was unexpected and profound. B cells infiltrated the tumor microenvironment in greater numbers, orchestrating complex immune responses that synergized with other immune components. This novel insight challenges the prevailing dogma that T cells are the sole immune warriors in solid tumors and suggests that modulating cancer metabolism can selectively amplify anti-tumor B cell activity.

At a mechanistic level, ACLY inhibition curtails the intracellular synthesis of acetyl-CoA derived from citrate, disrupting lipid biogenesis critical for membrane formation and energy storage in tumor cells. This lipid deprivation likely induces metabolic stress, exposing tumor-associated antigens and rendering cancer cells more visible to immune surveillance. Additionally, altering tumor metabolism may reshape cytokine profiles in the microenvironment, thereby recruiting and activating B cells more effectively.

Fatty liver disease, medically termed metabolic dysfunction–associated steatotic liver disease (MASLD), affects nearly eight million individuals in Canada alone, with a significant subset progressing to a more severe inflammatory state known as metabolic dysfunction-associated steatohepatitis (MASH). These patients bear a disproportionately high risk of developing aggressive liver cancers such as HCC, which historically has seen dismal survival rates—less than 20% of patients survive beyond five years. The introduction of EVT0185 and its ACLY-targeted mechanism offers a promising avenue to alter this grim prognosis.

In preclinical trials, murine models simulating human MASH coupled with HCC were treated with EVT0185, resulting in a marked reduction in both tumor burden and growth rate. Importantly, treated tumors exhibited heightened susceptibility to immune-mediated destruction, primarily through B cell engagement rather than the anticipated cytotoxic T cell pathways. This discovery opens new investigative directions into B cell biology within cancer and may inspire innovative immunotherapies designed to harness these cells’ full potential.

While promising, the research team acknowledges the complexity inherent in translating these findings to clinical practice. Future studies must unravel the precise immunological cascades initiated by ACLY inhibition, determine the safety and efficacy of EVT0185 in human subjects, and explore whether similar strategies can be effective across diverse malignancies with metabolic dependencies. Moreover, understanding how B cells communicate with other immune subsets in the tumor microenvironment will be crucial in designing comprehensive treatment protocols.

This investigation exemplifies the power of targeting cancer metabolism not merely as a metabolic reprogramming stance but as a strategic lever to remodel immune responses. By switching off a vital metabolic enzyme, researchers have demonstrated a capacity to “unmask” tumors and enlist underappreciated immune players in the eradication effort, thereby expanding the therapeutic landscape beyond conventional cytotoxic and checkpoint inhibitor approaches.

The study was made possible through funding from the Canadian Institutes of Health Research Foundation Grant and collaborative investment from Espervita Therapeutics, underscoring the increasing importance of academia-industry partnerships in advancing translational medicine. Notably, several authors maintain shareholder positions within Espervita, highlighting a close integration of research innovation and biotechnological development.

As this research paves the way for next-generation liver cancer therapies, it also sparks a broader imperative to revisit the metabolic underpinnings across other cancers. Metabolic enzymes like ACLY may constitute a new class of druggable targets capable of simultaneously disabling tumor nutrition and invigorating immune defenses. Such dual-action therapeutics could revolutionize oncological treatment paradigms, addressing resistance mechanisms and poor immunogenicity that have long hampered success.

In summary, the McMaster University and Espervita Therapeutics collaboration reveals a transformative approach to liver cancer treatment by inhibiting ACLY, the pivotal enzyme linking carbohydrate metabolism to fat synthesis. This intervention disrupts tumor metabolic homeostasis, triggers an unexpected B cell-driven immune response, and reduces tumor viability in preclinical models. While human trials are the next critical step, these findings significantly deepen our understanding of cancer immunometabolism and open promising avenues for combating one of the world’s deadliest cancers.

Subject of Research: Liver cancer metabolism and immune system interaction focusing on ACLY enzyme inhibition and B cell-mediated tumor immunity
Article Title: Inhibiting ACLY enhances tumour immunogenicity and resolves MASH-HCC
News Publication Date: 30-Jul-2025
Web References: 10.1038/s41586-025-09297-0
Keywords: Cancer, Liver cancer, Metabolism, Immunotherapy, B cells, ATP citrate lyase, Fatty liver disease, MASLD, MASH, Tumor microenvironment, Hepatocellular carcinoma, Immune metabolism

Hepatocellular carcinoma remains one of the leading causes of cancer-related mortality worldwide, with a dismal prognosis once tumors become refractory to frontline treatments. Current immunotherapies predominantly focus on PD-1 pathway inhibition, yet a significant subset of patients develop adaptive resistance or innate unresponsiveness, necessitating innovative combinatorial approaches. The phase 2 LIVERTI trial strategically investigates the concurrent blockade of PD-1 and TIGIT, a novel immune checkpoint receptor implicated in T cell exhaustion and immune evasion within the tumor microenvironment.

Domvanalimab, an investigational TIGIT-blocking antibody, functions by antagonizing TIGIT receptors on immune effector cells such as cytotoxic T lymphocytes and natural killer (NK) cells. TIGIT engagement typically dampens anti-tumor immune responses, facilitating tumor escape. Zimberelimab, acting as a PD-1 inhibitor, prevents PD-1 from interacting with its ligands PD-L1 and PD-L2, thereby reinvigorating T cell activity. The dual blockade aims to overcome compensatory inhibitory pathways that tumors exploit, restoring a robust immune-mediated cytotoxic assault on hepatocellular carcinoma cells resistant to prior PD-1 monotherapies.

Throughout this multicenter, open-label trial, patients with advanced HCC refractory to frontline PD-1 inhibitors received combined treatment with domvanalimab and zimberelimab. The cohort demonstrated promising clinical benefit, with increased objective response rates compared to historical controls receiving PD-1 inhibition alone. Enhanced progression-free survival was observed, suggesting durable disease control conferred by simultaneous inhibition of TIGIT and PD-1 pathways. Importantly, the safety profile remained manageable, with adverse events consistent with known effects of immune checkpoint blockade, including manageable immune-related toxicities.

Therapeutic resistance in HCC is multifactorial, involving an immunosuppressive tumor microenvironment enriched with regulatory T cells, myeloid-derived suppressor cells, and immunoinhibitory molecules. By targeting TIGIT, domvanalimab disrupts a critical suppressive axis that contributes to T cell exhaustion, thereby unleashing the cytolytic potential of CD8+ T cells and NK cells within the hepatic tumor milieu. PD-1 blockade with zimberelimab simultaneously prevents T cell anergy, effectuating a combinatorial immunomodulatory effect superior to single-agent checkpoint inhibition.

Advanced molecular analyses from patient biopsies underscore this synergy. Post-treatment tumor specimens exhibited elevated infiltration of activated CD8+ T cells expressing granzyme B and interferon-gamma, markers indicative of potent anti-tumor activity. Additionally, TIGIT expression on tumor-infiltrating lymphocytes decreased, corroborating effective receptor occupancy by domvanalimab. Transcriptomic profiling revealed upregulation of inflammatory cytokines and chemokines essential for sustaining an immune-activated state, further validating the mechanistic basis of this dual blockade strategy.

One of the critical revelations from the LIVERTI trial is the indication that TIGIT may serve as a compensatory checkpoint upregulated in response to PD-1 inhibition, representing a resistance mechanism exploited by HCC tumors. By concomitantly targeting both receptors, the trial provides compelling rationale for a new paradigm in immunotherapy where combination regimens are tailored to intercept multiple inhibitory signals within the tumor microenvironment. This approach holds promise for transforming outcomes not only in hepatocellular carcinoma but potentially across other PD-1 refractory malignancies.

The implications of this research transcend clinical efficacy. The LIVERTI trial pioneers a biomarker-driven framework for patient selection and therapeutic monitoring. Dynamic assessment of TIGIT and PD-1 expression levels, alongside immune cell phenotyping, may refine prognostication and optimize personalized treatment strategies. Such precision medicine approaches could maximize therapeutic benefit while minimizing unnecessary exposure and associated toxicities, marking a significant step toward adaptive tumor immunotherapy.

Moreover, this study sparks renewed interest in the biology of TIGIT, a relatively underexplored checkpoint receptor compared to CTLA-4 and PD-1. TIGIT’s role in modulating NK cell function and crosstalk with other immune checkpoints highlights its central position in immune homeostasis and tumor immune escape. Illuminating its pathways fosters drug development pipelines investigating next-generation agents that might synergize with current immunotherapies or serve as stand-alone modalities.

With the burgeoning landscape of immuno-oncology, combinatorial therapies such as domvanalimab plus zimberelimab exemplify strategic innovation aimed at surmounting resistance and enhancing durable clinical responses. The promising results reported in this phase 2 trial set the stage for larger, randomized studies to validate these findings and potentially secure regulatory approval for dual TIGIT/PD-1 blockade in refractory hepatocellular carcinoma. Such advancements could herald a new era in immunotherapy characterized by multipronged checkpoint inhibition tailored to tumor-specific immune landscapes.

In conclusion, the phase 2 LIVERTI trial delivers compelling evidence that targeting both TIGIT and PD-1 pathways using domvanalimab and zimberelimab may overcome resistance barriers inherent in hepatocellular carcinoma refractory to PD-1 monotherapy. This dual checkpoint blockade invigorates anti-tumor immunity, prolongs disease control, and maintains a tolerable safety profile, positioning this regimen as a frontrunner in next-generation immuno-oncology treatment paradigms. As the oncology community anticipates subsequent phase 3 data, these findings imbue hope for improved survival in one of the most intractable cancers.

Future research building upon this trial’s insights will likely entail mechanistic dissection of immune cell subpopulations mediating response, exploration of combinatorial strategies incorporating other immune modulators or targeted agents, and refinement of predictive biomarkers. The potential to effectively ‘reprogram’ the immunosuppressive tumor microenvironment through synergistic checkpoint blockade underscores the transformative promise of precision immunotherapy in combating refractory hepatocellular carcinoma.

In an era defined by immunotherapeutic breakthroughs, the LIVERTI trial underscores the value of rational combination checkpoint blockade to recalibrate anti-tumor immunity. By illuminating the therapeutic potential of targeting TIGIT alongside PD-1, this study propels the field closer to surmounting adaptive resistance mechanisms and achieving sustained remission for patients burdened by aggressive hepato-oncologic disease.

Subject of Research: Dual TIGIT and PD-1 checkpoint blockade therapy in hepatocellular carcinoma resistant to anti-PD-1 treatment

Article Title: Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial

Article References:

Hsiehchen, D., Kainthla, R., Kline, H. et al. Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial.
Nat Commun 16, 5819 (2025). https://doi.org/10.1038/s41467-025-60757-7

Image Credits: AI Generated

Liver cancer, particularly hepatocellular carcinoma (HCC), represents a formidable clinical challenge worldwide due to its notorious genetic heterogeneity and the scarcity of effective therapeutic targets. Conventional chemotherapeutic regimens often fall short, plagued by issues such as drug resistance and systemic toxicity. Consequently, there exists an urgent need to identify molecular targets that not only hamper tumor proliferation but also restore the normal cellular phenotype, thereby improving patient prognosis.

Central to this study is the role of Aurora kinases, a family of serine/threonine kinases known for their crucial involvement in mitotic progression and chromosomal stability. Dysregulation of Aurora kinases, especially Aurora A and Aurora B, has been implicated in tumorigenesis across various cancers, making them attractive candidates for targeted inhibition. However, their precise function in liver cancer differentiation had remained largely unexplored until now.

The investigators deployed potent Aurora kinase inhibitors, notably Alisertib and ENMD-2076, to assess their capacity to influence liver cancer cell behavior. Their experimental approach combined rigorous cellular assays with comprehensive gene expression analyses, revealing that treatment with these inhibitors not only curtailed cellular proliferation but also triggered a profound phenotypic shift. Remarkably, treated liver cancer cells exhibited transcriptional upregulation of a suite of hepatic differentiation markers, indicating a reversion toward a more differentiated, less malignant state.

This differentiation phenomenon was further characterized by a concomitant downregulation of malignancy-associated markers, underscoring the dual anti-tumorigenic effects of Aurora kinase inhibition. Importantly, these phenotypic changes persisted beyond the active presence of the drugs, maintained for several days post-withdrawal, suggesting a durable reprogramming of cancer cell identity—a feature that could translate into lasting clinical benefits.

Mechanistically, the study posits that Aurora kinase inhibitors mediate their effects through a bifurcated mechanism: the direct suppression of mitotic progression impairs unchecked cell division, while the induction of differentiation pathways reinstates hepatic cellular functions lost during oncogenesis. Transcriptomic profiling indicated activation of key hepatic transcription factors and metabolic genes, which collectively drive the maturation of malignant cells toward a more benign lineage-committed phenotype.

These findings also invite a reconsideration of how targeted therapies may be designed. Rather than exclusively striving to eradicate cancer cells via cytotoxicity, fostering differentiation represents an innovative paradigm that may mitigate adverse effects and circumvent resistance. By coaxing liver cancer cells to regain functionality akin to normal hepatocytes, Aurora kinase inhibitors could restore tissue homeostasis and inhibit tumor progression in a more physiologically congruent manner.

Furthermore, the inhibitors utilized—Alisertib and ENMD-2076—have demonstrated favorable pharmacokinetic and safety profiles in prior clinical evaluations across multiple cancer types. Their efficacy in inducing differentiation in liver cancer cells opens new vistas for clinical translation, potentially enabling combination regimens that integrate differentiation therapy with existing cytotoxic or immunotherapeutic modalities to achieve synergistic effects.

The implications of this study extend beyond the immediate clinical context as well. Understanding the molecular crosstalk between cell cycle regulation and differentiation not only enriches our comprehension of liver cancer biology but also fuels the development of next-generation therapeutics aimed at restoring cellular identity. Moreover, since Aurora kinases are universally expressed and implicated in diverse malignancies, the therapeutic concepts elucidated here may hold translational relevance across a spectrum of cancers.

Researchers emphasize that while these preclinical findings are promising, rigorous clinical investigations are imperative to evaluate the safety, optimal dosing, and long-term efficacy of Aurora kinase inhibitors in liver cancer patients. Additionally, elucidating the molecular determinants of responsiveness will be critical to stratify patients who stand to benefit most from differentiation-based therapies.

In summary, this study represents a significant leap forward in liver cancer research, revealing that targeting Aurora kinases extends beyond mere blockade of proliferation to encompass the induction of cellular differentiation. This dual action can potentially reshape therapeutic strategies aimed at this formidable malignancy, offering a beacon of hope for improved patient outcomes in the near future.

Subject of Research: Liver cancer treatment via Aurora kinase inhibition and induction of cellular differentiation.

Article Title: [Not Provided]

News Publication Date: [Not Provided]

Web References:
http://dx.doi.org/10.1007/s11427-023-2795-2

References:
[Study published in Science China Life Sciences, DOI: 10.1007/s11427-023-2795-2]

Image Credits: [Not Provided]

Keywords: Aurora kinases, liver cancer, hepatocellular carcinoma, cellular differentiation, Alisertib, ENMD-2076, targeted therapy, cancer biology, tumor proliferation, hepatic gene expression

Hepatocellular carcinoma remains one of the most lethal malignancies worldwide, largely due to late-stage diagnosis and limited therapeutic options once tumors reach an unresectable stage. Systemic therapies, including targeted agents and immune checkpoint inhibitors, have shown survival benefits but often fall short in achieving significant tumor downstaging. HAIC, which delivers high concentrations of chemotherapeutic agents directly into the liver’s arterial supply, has increasingly garnered attention as a locoregional approach with the potential to reduce tumor burden effectively while minimizing systemic toxicity.

This novel trial enrolled 19 patients diagnosed with advanced uHCC, all initially deemed unsuitable candidates for surgery. Participants received a carefully timed regimen combining apatinib, camrelizumab, and HAIC administered with the FOLFOX chemotherapy protocol, which includes oxaliplatin, leucovorin, and fluorouracil. The treatment cycles spanned 21-day intervals, extending to a maximum of eight cycles to maximize clinical response. Such an approach reflects an intricate balance of leveraging local chemotherapy infusion alongside systemic immune activation and angiogenesis inhibition.

The most striking outcome from this study was the achievement of conversion to resectability in nearly three-quarters of the patients. Specifically, 14 out of 19 participants exhibited sufficient tumor regression and favorable biological responses, making surgical intervention viable. Among them, nine patients proceeded to margin-free (R0) resections—surgical removals with no residual cancer cells detected at the margins—a gold standard for curative intent in oncologic surgery. These results underscore the potential that aggressive multimodal treatment harbors in transforming the clinical trajectory of traditionally inoperable liver cancers.

Notably, the pathological assessments post-surgery revealed that a third of these resected tumors demonstrated a major pathological response to the treatment, including two cases achieving complete pathological remission. This indicates that the combination therapy not only shrinks tumors radiographically but can also eliminate microscopic disease, an encouraging sign for long-term survival prospects. Furthermore, objective response rates approximated 47%, with disease control rates nearing 90%, according to RECIST (Response Evaluation Criteria In Solid Tumors) standards, highlighting a robust anti-tumor effect.

Importantly, the safety profile of this demanding regimen was manageable, albeit with considerable but expected toxicities. Over 70% of patients experienced grade 3 or higher treatment-related adverse events. Elevated liver enzymes and increased lymphocyte counts were the most frequent severe side effects. Encouragingly, no treatment-related mortality occurred, affirming that with vigilant monitoring and supportive care, this therapeutic strategy is tolerable for a majority of patients.

The underlying scientific rationale for this triple combination rests on synergistic mechanisms: HAIC delivers concentrated cytotoxic drugs directly to tumor vasculature, apatinib acts as a potent anti-angiogenic agent restricting tumor blood supply by inhibiting vascular endothelial growth factor receptor-2 (VEGFR-2), and camrelizumab unleashes the immune system by blocking PD-1 immune checkpoints. Together, these agents mount a multifaceted attack capable of overcoming tumor immune evasion and chemoresistance, which are critical challenges in advanced HCC.

This trial’s findings pave the way for further exploration of HAIC combined with immunotherapy and targeted agents as a conversion strategy, opening new doors to potentially curative surgery for patients previously resigned to palliative care. While survival data remain immature, the initial signals of tumor control and margin-negative resection bode well for improved outcomes. Future randomized controlled trials will be essential to validate these findings, optimize dosing schedules, and refine patient selection criteria.

Given the complexity of hepatocellular carcinoma’s biology and the heterogeneous nature of patient responses, the multidisciplinary integration of locoregional treatment, targeted therapy, and immunotherapy represents a tailored therapeutic frontier. This approach underscores a shift toward personalized oncology where combination regimens can be fine-tuned to elicit maximal tumor regression while maintaining quality of life.

The study also raises intriguing questions about the timing and sequencing of therapies. Administering camrelizumab shortly after apatinib initiation and preceding hepatic arterial infusion likely maximizes immune modulation and tumor microenvironment alteration, facilitating enhanced efficacy. Such precise coordination highlights the importance of understanding pharmacodynamics and immune interactions in devising effective treatment algorithms.

Beyond clinical efficacy, the trial exemplifies how advancements in interventional radiology and immuno-oncology can converge to extend the boundaries of cancer care. Hepatic artery infusion requires specialized expertise and infrastructure, underscoring the need for centers of excellence capable of delivering complex multimodal therapies safely and effectively.

While this treatment strategy currently applies to a select cohort of patients with unresectable hepatocellular carcinoma, its success may inspire similar combinatory frameworks for other solid tumors where surgical options are limited by advanced disease. The concept of conversion therapy, pushing tumors from inoperable to operable states, embodies a proactive and aggressive stance in cancer management.

In summary, the integration of HAIC using the FOLFOX regimen with camrelizumab and apatinib represents a significant leap forward in the therapeutic landscape of advanced hepatocellular carcinoma. The trial’s encouraging outcomes justify continued investigation and hope for a new standard of care that can improve survival and quality of life for a challenging patient population. As the oncology community anticipates further data, this innovative treatment offers a beacon of optimism for patients facing limited options.

Subject of Research: Conversion therapy for unresectable hepatocellular carcinoma using hepatic arterial infusion chemotherapy combined with immune checkpoint inhibition and targeted therapy.

Article Title: Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.

Article References:
Yalikun, K., Li, Z., Zhang, J. et al. Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial. BMC Cancer 25, 838 (2025). https://doi.org/10.1186/s12885-025-14250-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14250-5

Neddylation involves the covalent attachment of the ubiquitin-like protein NEDD8 to specific substrate proteins, a modification that fine-tunes protein function, stability, and interaction networks within the cell. Unlike ubiquitination, which primarily tags proteins for degradation, neddylation modulates the activity of a myriad of cellular regulators, particularly cullin-RING ligases (CRLs). These E3 ubiquitin ligases orchestrate the controlled degradation of numerous proteins that govern cell cycle progression, DNA repair, and signal transduction—processes that are frequently dysregulated in cancer.

In HCC, aberrations in the neddylation pathway have been implicated in enhanced tumor cell proliferation, invasion, and survival. Elevated levels of NEDD8-activating enzymes and downstream effectors correlate strongly with aggressive tumor phenotypes and poor patient outcomes. Mechanistically, neddylation hyperactivity fosters unchecked CRL function, leading to the proteasomal degradation of tumor suppressors and accumulation of oncogenic drivers. This disruption of protein homeostasis contributes to genomic instability and promotes malignant transformation in hepatocytes.

Given these insights, pharmaceutical inhibition of the neddylation cascade has emerged as a cutting-edge therapeutic avenue. Small molecule inhibitors such as MLN4924 (pevonedistat) and TAS4464 selectively target the NEDD8-activating enzyme (NAE), effectively halting the conjugation of NEDD8 to substrates. The blockade of this enzymatic step compromises CRL activity, resulting in the stabilization of tumor suppressor proteins and induction of cancer cell apoptosis. Preclinical models of HCC treated with these inhibitors demonstrate marked reductions in tumor growth, underscoring the clinical promise of this strategy.

The pharmacodynamics of neddylation inhibitors reveal multifaceted mechanisms of action. Treatment induces cell cycle arrest primarily at the G2/M checkpoint, impeding mitotic progression in cancer cells. Additionally, the accumulation of unrepaired DNA damage triggers intrinsic apoptotic pathways, further curbing tumor expansion. Notably, these agents exhibit selective toxicity towards malignant hepatocytes while sparing normal liver tissue, highlighting a favorable therapeutic index.

Beyond monotherapy, the potential synergy of neddylation inhibitors with established treatment modalities opens new horizons for combination regimens. Data suggest that integrating these inhibitors with immune checkpoint blockers amplifies antitumor immunity by enhancing cancer cell immunogenicity. Similarly, concomitant administration with sorafenib or other kinase inhibitors may potentiate cytostatic effects, providing a rational basis for multi-pronged treatment approaches in advanced HCC.

The advent of personalized medicine in liver oncology is further propelled by breakthroughs in biomarker discovery related to neddylation dysregulation. Molecular profiling of HCC patients reveals specific signatures of NEDD8 pathway activation, enabling risk stratification and tailored therapeutic selection. Early detection through these biomarkers promises to shift clinical practice towards prompt intervention, improving survival rates and reducing treatment-associated morbidity.

Understanding the intricate molecular interplay governed by neddylation in HCC also illuminates broader oncogenic networks. The pathway intersects with other post-translational modifications and epigenetic regulators, shaping the tumor microenvironment and influencing cancer stem cell dynamics. Consequently, unraveling these connections may uncover novel targets and refine current therapeutic paradigms further.

The clinical translation of neddylation-targeted therapies is already underway, with multiple phase I and II trials evaluating safety, pharmacokinetics, and efficacy in liver cancer cohorts. Initial findings demonstrate manageable side effect profiles and encouraging signs of antitumor activity, fueling optimism for future regulatory approval and widespread adoption. Continuous research aims to optimize dosing schedules and identify predictive markers of response to maximize patient benefit.

As the field progresses, it becomes increasingly clear that harnessing the therapeutic potential of neddylation modulation transcends liver cancer. Given its central role in cellular proteostasis, neddylation inhibitors may find applications across various malignancies characterized by aberrant CRL activity. This universality underscores the pivotal nature of this pathway in cancer biology and the transformative impact of its pharmacological targeting.

In sum, the exploration of neddylation in HCC represents a paradigm shift in understanding tumor biology and treatment. From molecular mechanisms to clinical applications, the insights gained lay the groundwork for innovative therapies that hold the promise of improved outcomes. The integration of neddylation inhibitors into comprehensive cancer care heralds a new chapter in combating one of the world’s most lethal malignancies, offering hope to patients and clinicians alike.

Subject of Research: Neddylation modification and its role in hepatocellular carcinoma progression and treatment

Article Title: Deciphering the roles of neddylation modification in hepatocellular carcinoma: Molecular mechanisms and targeted therapeutics

News Publication Date: 2025

References: Wenxin Wu, Xuanyi Wang, Ruijie Ma, Shuhong Huang, Hongguang Li, Xinxing Lyu, Genes & Diseases, volume 12, issue 4, 2025, 101483, DOI: 10.1016/j.gendis.2024.101483

Image Credits: Genes & Diseases

Keywords: Hepatocellular carcinoma, liver cancer, neddylation, NEDD8, post-translational modification, cancer therapy, MLN4924, pevonedistat, TAS4464, targeted therapeutics, tumor progression, personalized medicine

Hepatocellular carcinoma remains one of the most prevalent malignancies worldwide and carries a notoriously high recurrence rate following surgical resection. Such recurrences often present as unresectable lesions, demanding alternative therapeutic approaches. Despite advances in loco-regional therapies, no standardized treatment regimen currently exists for managing recurrent unresectable HCC, highlighting an urgent unmet clinical need.

The study, published in BMC Cancer, retrospectively analyzed clinical data from 83 patients diagnosed with recurrent unresectable HCC after initial surgery. The patients were stratified into three distinct treatment cohorts based on their regimens: a group receiving HAIC combined with TKIs and PD-1 inhibitors (HTP), a second group treated with TACE in combination with TKIs and PD-1 inhibitors (TTP), and a third control group undergoing TACE alone. This design enabled a robust comparative assessment of treatment efficacy and safety among cutting-edge combination therapies versus standard intervention.

HAIC and TACE are both hepatic artery-targeted therapies aimed at delivering chemotherapeutic agents directly to liver tumors, thereby maximizing local antitumor activity while limiting systemic toxicity. Combining these modalities with TKIs, which inhibit angiogenesis and tumor proliferation pathways, alongside PD-1 inhibitors that unleash anti-tumor immune responses, represents an innovative multimodal approach to tackle tumor progression on multiple fronts simultaneously.

The primary endpoint assessed was progression-free survival (PFS), a critical measure reflecting the duration during which patients remained free from disease advancement. Results revealed a marked improvement in median PFS among patients receiving combination therapy. Specifically, the HTP group demonstrated a median PFS of 13.7 months, substantially longer than the 9.2 months observed in the TTP group and dramatically exceeding the 2.5 months recorded for those treated with TACE alone. These findings underscore the additive benefit of incorporating both TKIs and PD-1 inhibitors alongside hepatic arterial infusion strategies.

Beyond survival metrics, tumor response was meticulously evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST), a standard for assessing therapeutic efficacy in HCC that accounts for changes in viable tumor tissue. The disease control rate (DCR), encompassing complete response (CR), partial response, and stable disease, was significantly higher in the HTP cohort at 89.7%, compared to 75.0% in the TTP group and only 50.0% with TACE monotherapy. The objective response rate (ORR), indicative of measurable tumor shrinkage, also favored combination regimens, reaching 44.8% and 35% in the HTP and TTP groups respectively, versus a mere 14.7% in the control group.

Remarkably, the incidence of complete response was restricted to the HTP group, with 17.2% of patients achieving this outcome. This contrasts starkly with a complete response rate of zero in both the TTP and TACE alone arms. Such results suggest that HAIC, when synergized with TKIs and PD-1 checkpoint blockade, may elicit profound antitumor effects potentially capable of eradicating clinically evident disease in a subset of patients.

Safety profiles across treatment arms were carefully monitored, revealing no occurrences of serious adverse reactions within the HTP and TTP groups. This highlights the tolerability of these combination regimens, which is pivotal considering the typically compromised hepatic reserve and overall frailty of advanced HCC patients. The absence of severe toxicity supports the feasibility of integrating immunotherapy and targeted agents with locoregional chemotherapy in clinical practice.

Mechanistically, the therapeutic synergy observed likely stems from complementary modes of action. TKIs suppress tumor angiogenesis and cellular proliferation, thereby restricting nutrient supply and direct tumor growth. PD-1 inhibitors enhance the host immune system’s capacity to recognize and destroy cancer cells by preventing immune checkpoint-mediated T cell exhaustion. Concurrently, HAIC and TACE deliver localized cytotoxic chemotherapy that induces tumor necrosis. This concerted attack disrupts the tumor microenvironment, potentially overcoming resistance mechanisms seen with monotherapy.

This study’s implications extend far beyond survival statistics. It emphasizes the evolving landscape of HCC treatment, where integrating systemic immunomodulation and targeted therapy with traditional intra-arterial chemotherapy heralds a new era of personalized oncology. Identifying patients most likely to benefit from such regimens remains an ongoing challenge, necessitating further biomarker-driven investigations.

Despite its retrospective design and relatively modest sample size, the research offers compelling evidence warranting prospective, randomized clinical trials to validate these findings. The ability to induce complete responses in previously refractory recurrent HCC patients could translate into durable remissions and improved overall survival, transforming standard care paradigms.

In summary, the combination of TKIs and PD-1 inhibitors with HAIC or TACE demonstrates superior efficacy and safety compared to TACE alone in treating recurrent unresectable hepatocellular carcinoma. Particularly, HAIC combined with these systemic agents achieves the highest complete response rates, shedding light on promising therapeutic avenues. As liver cancer continues to pose formidable clinical challenges, these findings pave the way toward more effective, multimodal treatment strategies that improve patient outcomes and quality of life.

Future research should aim to elucidate the molecular underpinnings driving response heterogeneity and resistance, optimize dosing schedules, and evaluate long-term survivorship benefits. Moreover, integrating advanced imaging modalities and liquid biopsy approaches may facilitate early detection of treatment response and recurrence, further refining clinical decision-making. Ultimately, multidisciplinary collaboration will be key to translating these scientific insights into routine clinical application.

The study stands as a testament to the rapidly advancing frontier of oncological therapeutics, underscoring the power of combining precision medicine, immunotherapy, and locoregional interventions. As these innovations converge, they offer renewed optimism for patients confronting the formidable challenge of recurrent unresectable hepatocellular carcinoma.

Subject of Research: Treatment efficacy and safety of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with hepatic arterial infusion chemotherapy/transarterial chemoembolization for recurrent unresectable hepatocellular carcinoma.

Article Title: The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

Article References:
Deng, W., Xie, J., Wang, T. et al. The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma. BMC Cancer 25, 779 (2025). https://doi.org/10.1186/s12885-025-14185-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14185-x